A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors

The IGF pathway has been implicated in the regulation of neuroendocrine tumor (NET) growth, and preliminary studies suggested that ganitumab (AMG 479), a human MAB against IGF1R, may have antitumor activity in this setting. We performed a two-cohort phase II study of ganitumab in patients with metas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Strosberg, J R, Chan, J A, Ryan, D P, Meyerhardt, J A, Fuchs, C S, Abrams, T, Regan, E, Brady, R, Weber, J, Campos, T, Kvols, L K, Kulke, M H
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4029434/
https://ncbi.nlm.nih.gov/pubmed/23572164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-12-0390
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados